Skip to main content

Conference Correspondent

News, views, and coverage of important topics and discussions from oncology conferences and events.

[widgetkit id="2" name="CC Highlights"]

AACR & ASCO 2021 - Midyear Review

Phase 2 Study of D-0316 in Patients with Advanced NSCLC and EGFR T790M Mutation

AACR & ASCO 2021 - Midyear Review

Phase 2 Study of Osimertinib + Oleclumab in Progressive T790M-Negative EGFR-Mutated NSCLC

AACR & ASCO 2021 - Midyear Review

Safety Results of Phase 2 Study of Bintrafusp plus Chemotherapy in Advanced NSCLC (INTR@PID LUNG 024)

AACR & ASCO 2021 - Midyear Review

Randomized Phase 3 Study of Sintilimab versus Docetaxel in Advanced Squamous NSCLC (ORIENT-3)

AACR & ASCO 2021 - Midyear Review

Phase 3 Study of Tislelizumab Compared with Docetaxel in Advanced NSCLC (RATIONALE 303)

AACR & ASCO 2021 - Midyear Review

Acquired Resistance Mutations After Treatment of EGFR-Mutated Metastatic NSCLC with Osimertinib plus Savolitinib (TATTON)

AACR & ASCO 2021 - Midyear Review

Combination of Nivolumab and Chemotherapy in Nonmetastatic Resectable NSCLC (CheckMate-816)

AACR & ASCO 2021 - Midyear Review

Combination Therapies and New Molecular Targets—Presentations from AACR 2021

David Spigel, MD

AACR & ASCO 2021 - Midyear Review

Key Abstracts from ASCO 2021 in NSCLC

Mark A. Socinski, MD

AACR & ASCO 2021 - Midyear Review

Practice-Changing Data in NSCLC from ASCO 2021

Mark A. Socinski, MD

1
2
3
4
5
6
7

Page 4 of 22
Results 31 - 40 of 219